Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells.
EMT
HDAC
HDI
MET
cadherin
cancer
catenin
invasion
migration
vimentin
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Jan 2019
27 Jan 2019
Historique:
received:
23
12
2018
revised:
18
01
2019
accepted:
22
01
2019
entrez:
30
1
2019
pubmed:
30
1
2019
medline:
30
1
2019
Statut:
epublish
Résumé
Histone deacetylase inhibitors (HDIs) are a group of potent epigenetic drugs which have been investigated for their therapeutic potential in various clinical disorders, including hematological malignancies and solid tumors. Currently, several HDIs are already in clinical use and many more are on clinical trials. HDIs have shown efficacy to inhibit initiation and progression of cancer cells. Nevertheless, both pro-invasive and anti-invasive activities of HDIs have been reported, questioning their impact in carcinogenesis. The aim of this review is to compile and discuss the most recent findings on the effect of HDIs on the epithelial-mesenchymal transition (EMT) process in human cancers. We have summarized the impact of HDIs on epithelial (E-cadherin, β-catenin) and mesenchymal (N-cadherin, vimentin) markers, EMT activators (
Identifiants
pubmed: 30691229
pii: cancers11020148
doi: 10.3390/cancers11020148
pmc: PMC6406474
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : The Polish Ministry of Science and Higher Education, Polish National Science Centre
ID : DS440/2018-2019, MNmb 402/2018-2019, MNmb 510/2016-2017, DEC-2015/17/B/NZ1/01777 and DEC-2017/25/B/NZ4/02364
Références
Mol Cell. 2002 Jan;9(1):45-57
pubmed: 11804585
Int J Cancer. 2002 Feb 10;97(5):567-73
pubmed: 11807779
J Biol Chem. 2002 Jul 19;277(29):25904-13
pubmed: 11994312
EMBO J. 2002 Dec 2;21(23):6539-48
pubmed: 12456660
Cell. 2002 Nov 27;111(5):709-20
pubmed: 12464182
Biochemistry. 2004 Sep 14;43(36):11500-15
pubmed: 15350136
J Biol Chem. 2005 Jun 10;280(23):21797-803
pubmed: 15831498
Biochemistry. 2005 Apr 26;44(16):6312-20
pubmed: 15835920
Postepy Hig Med Dosw (Online). 2005 Mar 11;59:68-74
pubmed: 15928589
J Biol Chem. 2005 Jul 22;280(29):26729-34
pubmed: 15937340
Gene. 2005 Dec 19;363:15-23
pubmed: 16289629
J Am Soc Nephrol. 2007 Jan;18(1):58-65
pubmed: 17135397
Oncogene. 2007 Aug 13;26(37):5310-8
pubmed: 17694074
Oncogene. 2007 Aug 13;26(37):5450-67
pubmed: 17694086
Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17335-40
pubmed: 17956988
Cancer Gene Ther. 2009 Feb;16(2):137-48
pubmed: 18772901
Nat Rev Genet. 2009 Jan;10(1):32-42
pubmed: 19065135
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Mol Cancer Ther. 2010 Dec;9(12):3254-66
pubmed: 21041383
PLoS One. 2011 Jan 31;6(1):e16530
pubmed: 21304978
J Antibiot (Tokyo). 2011 Aug;64(8):525-31
pubmed: 21587264
J Cell Physiol. 2011 Sep;226(9):2378-90
pubmed: 21660961
Mol Cancer Res. 2011 Dec;9(12):1608-20
pubmed: 21840933
PLoS One. 2011;6(8):e24099
pubmed: 21909380
Cell Mol Life Sci. 2012 Aug;69(15):2527-41
pubmed: 22349261
Neurol Med Chir (Tokyo). 2012;52(4):186-93
pubmed: 22522328
Urol Oncol. 2013 Nov;31(8):1770-9
pubmed: 22944197
Am J Cancer Res. 2012;2(5):589-97
pubmed: 22957310
Stem Cells. 2012 Nov;30(11):2366-77
pubmed: 22961641
Mol Oncol. 2012 Dec;6(6):579-89
pubmed: 22963873
Int J Cancer. 2013 May 1;132(9):2200-8
pubmed: 23024001
J Cell Sci. 2012 Oct 1;125(Pt 19):4417-22
pubmed: 23165231
Br J Cancer. 2013 Feb 19;108(3):579-86
pubmed: 23370212
Epigenomics. 2013 Feb;5(1):87-94
pubmed: 23414323
J Pharmacol Exp Ther. 2013 May;345(2):206-14
pubmed: 23461975
Mol Cancer. 2013 Oct 05;12(1):114
pubmed: 24093956
Curr Cancer Drug Targets. 2013 Nov;13(9):963-972
pubmed: 24168186
AIDS. 2013 Nov 28;27(18):2853-62
pubmed: 24189584
Zhonghua Er Ke Za Zhi. 2013 Jul;51(7):552-4
pubmed: 24267144
Breast Cancer Res Treat. 2014 Jan;143(1):99-111
pubmed: 24305977
BMC Cancer. 2014 Jan 13;14:17
pubmed: 24418474
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Cold Spring Harb Perspect Biol. 2014 Apr 01;6(4):a018713
pubmed: 24691964
Int J Biochem Cell Biol. 2014 Jun;51:102-10
pubmed: 24721210
Breast Cancer Res Treat. 2014 Jun;145(3):593-604
pubmed: 24810497
ACS Med Chem Lett. 2012 Apr 26;3(6):505-8
pubmed: 24900500
J Exp Clin Cancer Res. 2014 Jul 10;33:59
pubmed: 25011684
Drug Discov Today Technol. 2014 Jun;12:e9-e17
pubmed: 25027380
Trends Pharmacol Sci. 2014 Sep;35(9):479-88
pubmed: 25042456
Nat Rev Drug Discov. 2014 Sep;13(9):673-91
pubmed: 25131830
Expert Opin Investig Drugs. 2015 Jan;24(1):69-78
pubmed: 25216628
J Clin Invest. 2014 Dec;124(12):5453-65
pubmed: 25384215
Br J Haematol. 2015 Mar;168(6):811-9
pubmed: 25404094
Front Cell Neurosci. 2014 Nov 13;8:382
pubmed: 25431550
Biochem Biophys Res Commun. 2015 Jan 2;456(1):320-6
pubmed: 25434997
Oncol Rep. 2015 May;33(5):2299-308
pubmed: 25813246
EMBO Mol Med. 2015 Apr 14;7(6):831-47
pubmed: 25872941
Clin Transl Med. 2015 Apr 14;4:14
pubmed: 25932287
Oncotarget. 2015 Jun 30;6(18):15966-83
pubmed: 25965826
World J Clin Cases. 2015 May 16;3(5):393-404
pubmed: 25984514
Front Oncol. 2015 May 26;5:108
pubmed: 26075180
J Cancer Res Clin Oncol. 2016 Jan;142(1):177-85
pubmed: 26206483
Tumour Biol. 2016 Jan;37(1):931-42
pubmed: 26260271
Lung. 2015 Oct;193(5):691-700
pubmed: 26286207
Curr Top Med Chem. 2016;16(7):714-31
pubmed: 26303421
Biol Chem. 2016 Jan;397(1):75-83
pubmed: 26431101
Oncotarget. 2015 Nov 3;6(34):35991-6002
pubmed: 26462017
BMC Gastroenterol. 2015 Oct 26;15:148
pubmed: 26502922
PLoS One. 2015 Nov 18;10(11):e0143013
pubmed: 26580554
Oncogene. 2016 Jul 21;35(29):3781-95
pubmed: 26640144
PLoS One. 2016 Jan 04;11(1):e0145985
pubmed: 26726879
Mol Cancer Ther. 2016 Feb;15(2):299-312
pubmed: 26772204
Biochim Biophys Acta. 2016 Apr;1865(2):275-88
pubmed: 27085853
Biomol Concepts. 2016 May 1;7(2):103-16
pubmed: 27101554
Leuk Lymphoma. 2016 Aug;57(8):1755-65
pubmed: 27118119
Int J Neuropsychopharmacol. 2016 Aug 12;19(8):
pubmed: 27207921
Clin Pharmacol. 2016 May 06;8:35-44
pubmed: 27226735
Bioorg Chem. 2016 Aug;67:18-42
pubmed: 27239721
Target Oncol. 2016 Dec;11(6):783-798
pubmed: 27250763
Sci Rep. 2016 Jun 13;6:28004
pubmed: 27292433
Eur J Med Chem. 2016 Oct 4;121:451-483
pubmed: 27318122
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
J Cell Mol Med. 2016 Dec;20(12):2289-2298
pubmed: 27420561
Cell Biol Toxicol. 2016 Dec;32(6):469-482
pubmed: 27423454
Hepatol Res. 2017 Feb;47(2):149-159
pubmed: 27457249
Sci Rep. 2016 Aug 04;6:31093
pubmed: 27489122
BMC Cancer. 2016 Aug 09;16:617
pubmed: 27506904
Cell Death Discov. 2016 Jun 06;2:16036
pubmed: 27551526
Cell Death Discov. 2016 Jun 13;2:16041
pubmed: 27551531
PLoS One. 2016 Aug 29;11(8):e0162058
pubmed: 27571418
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jan 4;72:60-72
pubmed: 27614213
PLoS One. 2016 Oct 20;11(10):e0164811
pubmed: 27764163
Int J Oncol. 2016 Nov;49(5):1859-1869
pubmed: 27826618
J Neuroinflammation. 2016 Dec 1;13(1):300
pubmed: 27905989
Anticancer Res. 2017 Jan;37(1):35-46
pubmed: 28011471
Am J Cancer Res. 2016 Dec 01;6(12):2831-2845
pubmed: 28042503
Epigenomics. 2017 Apr;9(4):447-461
pubmed: 28102705
J Cancer. 2017 Jan 1;8(1):19-28
pubmed: 28123594
Prostate. 2017 May;77(7):776-793
pubmed: 28181686
Expert Rev Mol Med. 2017 Mar 21;19:e3
pubmed: 28322181
Nucleic Acids Res. 2017 Jun 20;45(11):6334-6349
pubmed: 28369619
Dev Dyn. 2018 Mar;247(3):432-450
pubmed: 28407379
Cancer Treat Rev. 2017 Apr;55:200-208
pubmed: 28431263
Urol Oncol. 2017 Sep;35(9):544.e11-544.e23
pubmed: 28551413
Am J Cancer Res. 2017 May 01;7(5):1213-1226
pubmed: 28560068
Cancer Res. 2017 Aug 15;77(16):4228-4237
pubmed: 28625977
J Cancer. 2017 May 12;8(8):1453-1459
pubmed: 28638460
NPJ Breast Cancer. 2017 Jun 6;3:21
pubmed: 28649661
Pathol Res Pract. 2017 Nov;213(11):1329-1339
pubmed: 28882400
Trends Genet. 2017 Dec;33(12):943-959
pubmed: 28919019
Biochem Biophys Res Commun. 2017 Dec 2;493(4):1534-1541
pubmed: 28993195
Mol Cancer. 2017 Nov 10;16(1):170
pubmed: 29126425
Biomed Pharmacother. 2018 Jan;97:1445-1453
pubmed: 29156535
Anticancer Drugs. 2018 Jan;29(1):80-88
pubmed: 29176396
Prostate. 2018 Mar;78(4):266-277
pubmed: 29243324
Crit Rev Oncol Hematol. 2018 Jan;121:11-22
pubmed: 29279096
Oncotarget. 2017 Nov 30;8(66):110367-110379
pubmed: 29299154
Clin Epigenetics. 2018 Jan 4;10:1
pubmed: 29312470
Cancer Lett. 2018 Apr 28;420:1-13
pubmed: 29410023
Front Oncol. 2018 Mar 29;8:92
pubmed: 29651407
Nature. 2018 Apr;556(7702):463-468
pubmed: 29670281
Oncol Rep. 2018 Jul;40(1):346-354
pubmed: 29767267
Arch Toxicol. 2018 Jul;92(7):2227-2243
pubmed: 29845424
Nutrients. 2018 Jun 06;10(6):null
pubmed: 29882797
Dev Cell. 2018 Jun 18;45(6):663-665
pubmed: 29920271
Clin Epigenetics. 2018 Jul 31;10(1):100
pubmed: 30064501
Exp Cell Res. 2018 Oct 1;371(1):231-237
pubmed: 30107147
Nat Cell Biol. 2018 Dec;20(12):1400-1409
pubmed: 30455462
Nat Rev Mol Cell Biol. 2019 Mar;20(3):156-174
pubmed: 30467427
Expert Rev Mol Diagn. 2018 Dec 19;:1-10
pubmed: 30563379
Genes Dis. 2018 Jun 18;5(4):304-311
pubmed: 30591931
Genes Dev. 1995 May 15;9(10):1188-98
pubmed: 7758944
Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9855-60
pubmed: 9707565
Nature. 1998 Dec 10;396(6711):594-8
pubmed: 9859997